Phenyl-sulfinyl-sulfamoylphenyl-benzamide derivatives that inhibit voltage-gated sodium channels

    公开(公告)号:NZ596413A

    公开(公告)日:2013-03-28

    申请号:NZ59641307

    申请日:2007-04-11

    Applicant: VERTEX PHARMA

    Abstract: ABSTRACT - 596413 The disclosure relates to phenylsulfinyl-3-sulfamoylphenyl-benzamide compounds of formula (I), which are useful as inhibitors of voltage-gated sodium channels, wherein the variables are as defined in the specification. The disclosure also provides pharmaceutically acceptable compositions comprising said compounds and their use for treating or lessening the severity in a subject of acute, chronic, neuropathic, or inflammatory pain, arthritis, migraine, cluster headaches, epilepsy, neurodegenerative disorders, psychiatric disorders, anxiety, depression, dipolar disorder, myotonia, arrhythmia, movement disorders, neuroendocrine disorders, ataxia, multiple sclerosis, irritable bowel syndrome, incontinence, visceral pain, osteoarthritis pain, back pain, head pain, neck pain, severe pain, intractable pain, nociceptive pain, breakthrough pain, postsurgical pain, cancer pain, stroke, cerebral ischemia, traumatic brain injury, amyotrophic lateral sclerosis, stress-induced angina, exercise induced angina, palpitations, hypertension, migraine, or abnormal gastro-intestinal motility.

    AMIDES USEFUL AS INHIBITORS OF VOLTAGE-GATED SODIUM CHANNELS

    公开(公告)号:NZ584474A

    公开(公告)日:2012-06-29

    申请号:NZ58447408

    申请日:2008-10-10

    Applicant: VERTEX PHARMA

    Abstract: Disclosed are amide compounds represented by general formula (I). An example of a compound of formula (I) is 4-tert-Butyl-N-(5-(methylsulfonyl)pyridin-3-yl)-2-(6-trifluoromethyl)pyridin-3-yloxy)benzamide. The compounds of formula (I) are used to treat acute, chronic, neuropathic, or inflammatory pain, arthritis, migraine, cluster headaches, trigeminal neuralgia, herpetic neuralgia, general neuralgias, epilepsy or epilepsy conditions, neurodegenerative disorders, psychiatric disorders such as anxiety and depression, dipolar disorder, myotonia, arrhythmia, movement disorders, neuroendocrine disorders, ataxia, multiple sclerosis, irritable bowel syndrome, incontinence, visceral pain, osteoarthritis pain, postherpetic neuralgia, diabetic neuropathy, radicular pain, sciatica, back pain, head or neck pain, severe or intractable pain, nociceptive pain, breakthrough pain, postsurgical pain, cancer pain, stroke, cerebral ischemia, traumatic brain injury, amyotrophic lateral sclerosis, stress- or exercise induced angina, palpitations, hypertension, migraine, or abnormal gastro-intestinal motility.

Patent Agency Ranking